Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 13 studies | 28% ± 13% | |
| classical monocyte | 8 studies | 25% ± 9% | |
| monocyte | 7 studies | 22% ± 4% | |
| brush cell | 4 studies | 30% ± 18% | |
| alveolar macrophage | 3 studies | 21% ± 6% |
Insufficient scRNA-seq data for expression of CD300LF at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 1088.27 | 578 / 578 | 89% | 10.41 | 1026 / 1155 |
| intestine | 63% | 107.78 | 605 / 966 | 69% | 4.35 | 362 / 527 |
| breast | 46% | 36.12 | 212 / 459 | 82% | 4.68 | 912 / 1118 |
| bladder | 67% | 71.00 | 14 / 21 | 60% | 4.18 | 301 / 504 |
| kidney | 42% | 40.16 | 37 / 89 | 82% | 7.22 | 735 / 901 |
| pancreas | 20% | 18.05 | 67 / 328 | 87% | 10.04 | 155 / 178 |
| prostate | 67% | 56.64 | 163 / 245 | 41% | 1.46 | 204 / 502 |
| brain | 45% | 45.95 | 1201 / 2642 | 60% | 3.78 | 422 / 705 |
| stomach | 31% | 23.82 | 112 / 359 | 72% | 4.94 | 205 / 286 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 29.21 | 29 / 29 |
| spleen | 100% | 2306.93 | 241 / 241 | 0% | 0 | 0 / 0 |
| thymus | 31% | 23.88 | 203 / 653 | 67% | 3.58 | 403 / 605 |
| uterus | 34% | 21.41 | 57 / 170 | 59% | 3.51 | 273 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 84% | 7.49 | 38 / 45 |
| peripheral blood | 82% | 3348.62 | 765 / 929 | 0% | 0 | 0 / 0 |
| liver | 45% | 33.14 | 102 / 226 | 37% | 1.68 | 149 / 406 |
| esophagus | 26% | 17.84 | 378 / 1445 | 51% | 2.31 | 94 / 183 |
| adrenal gland | 61% | 45.19 | 158 / 258 | 16% | 0.64 | 37 / 230 |
| adipose | 66% | 72.56 | 792 / 1204 | 0% | 0 | 0 / 0 |
| skin | 2% | 0.94 | 30 / 1809 | 62% | 4.80 | 291 / 472 |
| ovary | 17% | 10.30 | 31 / 180 | 44% | 1.97 | 190 / 430 |
| blood vessel | 37% | 40.00 | 495 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 25% | 1.09 | 20 / 80 |
| heart | 20% | 14.71 | 175 / 861 | 0% | 0 | 0 / 0 |
| muscle | 1% | 0.76 | 12 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0035666 | Biological process | TRIF-dependent toll-like receptor signaling pathway |
| GO_0035772 | Biological process | interleukin-13-mediated signaling pathway |
| GO_0034125 | Biological process | negative regulation of MyD88-dependent toll-like receptor signaling pathway |
| GO_2000426 | Biological process | negative regulation of apoptotic cell clearance |
| GO_2000427 | Biological process | positive regulation of apoptotic cell clearance |
| GO_0033004 | Biological process | negative regulation of mast cell activation |
| GO_1902216 | Biological process | positive regulation of interleukin-4-mediated signaling pathway |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0005136 | Molecular function | interleukin-4 receptor binding |
| GO_0001786 | Molecular function | phosphatidylserine binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0097001 | Molecular function | ceramide binding |
| GO_0042802 | Molecular function | identical protein binding |
| Gene name | CD300LF |
| Protein name | CD300 molecule like family member f CMRF35-like molecule 1 (CLM-1) (CD300 antigen-like family member F) (Immune receptor expressed on myeloid cells 1) (IREM-1) (Immunoglobulin superfamily member 13) (IgSF13) (NK inhibitory receptor) (CD antigen CD300f) |
| Synonyms | CD300F IGSF13 NKIR UNQ3105/PRO10111 CLM1 IREM1 |
| Description | FUNCTION: Acts as an inhibitory receptor for myeloid cells and mast cells . Positively regulates the phagocytosis of apoptotic cells (efferocytosis) via phosphatidylserine (PS) recognition; recognizes and binds PS as a ligand which is expressed on the surface of apoptotic cells. Plays an important role in the maintenance of immune homeostasis, by promoting macrophage-mediated efferocytosis and by inhibiting dendritic cell-mediated efferocytosis (By similarity). Negatively regulates Fc epsilon receptor-dependent mast cell activation and allergic responses via binding to ceramide and sphingomyelin which act as ligands . May act as a coreceptor for interleukin 4 (IL-4). Associates with and regulates IL-4 receptor alpha-mediated responses by augmenting IL-4- and IL-13-induced signaling (By similarity). Negatively regulates the Toll-like receptor (TLR) signaling mediated by MYD88 and TRIF through activation of PTPN6/SHP-1 and PTPN11/SHP-2 . Inhibits osteoclast formation. Induces macrophage cell death upon engagement (By similarity). . |
| Accessions | ENST00000361254.8 [Q8TDQ1-2] ENST00000581500.1 [Q8TDQ1-2] ENST00000326165.11 [Q8TDQ1-1] ENST00000583937.5 J3KS52 ENST00000462044.5 [Q8TDQ1-3] ENST00000469092.5 [Q8TDQ1-4] Q8TDQ1 ENST00000464910.5 [Q8TDQ1-6] ENST00000343125.8 [Q8TDQ1-4] ENST00000301573.13 [Q8TDQ1-5] |
